These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 11237491)
41. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection. Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285 [TBL] [Abstract][Full Text] [Related]
42. Serum CA 242 and CEA detect different patients with recurrent colorectal cancer. Carpelan-Holmström MA; Haglund CH; Järvinen HJ; Roberts PJ Anticancer Res; 1996; 16(2):981-6. PubMed ID: 8687164 [TBL] [Abstract][Full Text] [Related]
43. A comparative analysis of the serum levels of NCC-ST-439, CEA and CA19-9 in patients with colorectal carcinoma. Iemura K; Moriya Y Eur J Surg Oncol; 1993 Oct; 19(5):439-42. PubMed ID: 8405479 [TBL] [Abstract][Full Text] [Related]
44. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer. Fernández-Fernández L; Tejero E; Tieso A; Rabadán L; Munoz M; Santos I Int Surg; 1996; 81(4):400-2. PubMed ID: 9127805 [TBL] [Abstract][Full Text] [Related]
45. Elevated plasma gastrin, CEA, and CA 19-9 levels decrease after colorectal cancer resection. Bombski G; Gasiorowska A; Orszulak-Michalak D; Neneman B; Kotynia J; Strzelczyk J; Janiak A; Malecka-Panas E Int J Colorectal Dis; 2003 Mar; 18(2):148-52. PubMed ID: 12548418 [TBL] [Abstract][Full Text] [Related]
46. Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Wang JY; Lu CY; Chu KS; Ma CJ; Wu DC; Tsai HL; Yu FJ; Hsieh JS Eur Surg Res; 2007; 39(4):245-50. PubMed ID: 17457032 [TBL] [Abstract][Full Text] [Related]
47. [Measurement of serum protein-bound hexose--an aid in the diagnosis and after-care of colorectal cancers?]. Putzki H; Reichert B; Hue M Zentralbl Chir; 1992; 117(6):331-3. PubMed ID: 1519392 [TBL] [Abstract][Full Text] [Related]
48. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797 [TBL] [Abstract][Full Text] [Related]
50. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring. Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Liu BY; Zhu ZG J Gastroenterol Hepatol; 2005 Dec; 20(12):1913-9. PubMed ID: 16336453 [TBL] [Abstract][Full Text] [Related]
51. Utility of serum preoperative carcinoemberyonic antigen in colorectal cancer patients. El-Awady S; Lithy R; Morshed M; Khafagy W; Abd Monem H; Waleed O; Badr S; Fekry A; El Nakeeb A; Ghazy H; El Yamany M; Metwally T; El-Arman M; Farid M Hepatogastroenterology; 2009; 56(90):361-6. PubMed ID: 19579599 [TBL] [Abstract][Full Text] [Related]
52. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen. Huber K; Kirchheimer JC; Sedlmayer A; Bell C; Ermler D; Binder BR Cancer Res; 1993 Apr; 53(8):1788-93. PubMed ID: 8467497 [TBL] [Abstract][Full Text] [Related]
53. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242. Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604 [TBL] [Abstract][Full Text] [Related]
54. The effect of colonoscopy on tumor markers. Scapa E; Broide E; Pinhasov I Surg Laparosc Endosc; 1997 Dec; 7(6):477-9. PubMed ID: 9438630 [TBL] [Abstract][Full Text] [Related]
55. [CA 15-3 associated with CEA and TPA in the follow-up of breast carcinoma]. Maffei S; Rudoni M; Antonini G; Sacchetti G; Krengli M Minerva Med; 1990 Nov; 81(11):759-63. PubMed ID: 2255409 [TBL] [Abstract][Full Text] [Related]
56. Carcinoembryonic antigen and CA19-9: implications of quantitative marker measurement in tissues for prognosis of colorectal cancer. Gebauer G; Müller-Ruchholtz W Cancer Detect Prev; 2001; 25(4):344-51. PubMed ID: 11531011 [TBL] [Abstract][Full Text] [Related]
57. [Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients]. Grotowski M; Maruszyński M; Piechota W Pol Merkur Lekarski; 2001 Dec; 11(66):476-9. PubMed ID: 11899841 [TBL] [Abstract][Full Text] [Related]
58. Tumor markers in staging and prognosis of colorectal carcinoma. Levy M; Visokai V; Lipska L; Topolcan O Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252 [TBL] [Abstract][Full Text] [Related]
59. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733 [TBL] [Abstract][Full Text] [Related]
60. Clinical utility of CA 72-4 serum marker in the staging and immediate post-surgical management of gastric cancer patients. Spila A; Roselli M; Cosimelli M; Ferroni P; Cavaliere F; Arcuri R; Tedesco M; Carlini S; D'Alessandro R; Perri P; Casciani CU; Greiner JW; Schlom J; Guadagni F Anticancer Res; 1996; 16(4B):2241-7. PubMed ID: 8694550 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]